Limits...
Effects of Hormone Therapy on Oxidative Stress in Postmenopausal Women with Metabolic Syndrome

View Article: PubMed Central - PubMed

ABSTRACT

The aim of this study was to determine the effect of oral hormone therapy (HT) on oxidative stress (OS) in postmenopausal women with metabolic syndrome (MetS). A randomized, double blind, placebo-controlled trial was carried out. We formed four groups of 25 women each; healthy (HW) and MetS women (MSW) were assigned to HT (1 mg/day of estradiol valerate plus 5 mg/10 day of medroxiprogesterone) or placebo. We measured plasma lipoperoxides, erythrocyte superoxide dismutase and glutathione peroxidase, total plasma antioxidant status and uric acid, as OS markers. Alternative cut-off values of each parameter were defined and a stress score (SS) ranging from 0 to 7 was used as total OS. MetS was defined according to National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATPIII) criteria. Participants were seen at baseline, 3 and 6 months. After 6 months, MetS decreased in MSW-HT (48%), their triglycerides and high-density lipoprotein cholesterol (HDL-c) improved; in the other groups no difference was found. SS in MSW-HT decreased (3.8 ± 0.3 to 1.7 ± 0.3, p < 0.05) and OS was also reduced (44%), this effect was evident since 3 mo. HW-HT with high OS also decreased (40%). In placebo groups there was no change. Our findings suggest that HT improve lipids and OS associated to MetS in postmenopausal women.

No MeSH data available.


Related in: MedlinePlus

Stress score in the three moments of measure by the study group. Data is expressed as a mean ± standard error. Repeated measure analysis of variance (ANOVA) test, time by group (p < 0.01). Paired t-test: ap < 0.05; bp = 0.001; cp < 0.0001. MetS: metabolic syndrome; HT: hormone therapy.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC5037668&req=5

ijms-17-01388-f002: Stress score in the three moments of measure by the study group. Data is expressed as a mean ± standard error. Repeated measure analysis of variance (ANOVA) test, time by group (p < 0.01). Paired t-test: ap < 0.05; bp = 0.001; cp < 0.0001. MetS: metabolic syndrome; HT: hormone therapy.

Mentions: Oxidative stress score (SS) declined during the course of the study in the two groups with HT, but the effect was highest in the women with MetS because a significant reduction of SS was observed as early as 3 months; in HW, the antioxidant effect was seen until month 6. In both placebo groups, SS decreased at month 3 but increased again at end of follow-up (Figure 2).


Effects of Hormone Therapy on Oxidative Stress in Postmenopausal Women with Metabolic Syndrome
Stress score in the three moments of measure by the study group. Data is expressed as a mean ± standard error. Repeated measure analysis of variance (ANOVA) test, time by group (p < 0.01). Paired t-test: ap < 0.05; bp = 0.001; cp < 0.0001. MetS: metabolic syndrome; HT: hormone therapy.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC5037668&req=5

ijms-17-01388-f002: Stress score in the three moments of measure by the study group. Data is expressed as a mean ± standard error. Repeated measure analysis of variance (ANOVA) test, time by group (p < 0.01). Paired t-test: ap < 0.05; bp = 0.001; cp < 0.0001. MetS: metabolic syndrome; HT: hormone therapy.
Mentions: Oxidative stress score (SS) declined during the course of the study in the two groups with HT, but the effect was highest in the women with MetS because a significant reduction of SS was observed as early as 3 months; in HW, the antioxidant effect was seen until month 6. In both placebo groups, SS decreased at month 3 but increased again at end of follow-up (Figure 2).

View Article: PubMed Central - PubMed

ABSTRACT

The aim of this study was to determine the effect of oral hormone therapy (HT) on oxidative stress (OS) in postmenopausal women with metabolic syndrome (MetS). A randomized, double blind, placebo-controlled trial was carried out. We formed four groups of 25 women each; healthy (HW) and MetS women (MSW) were assigned to HT (1 mg/day of estradiol valerate plus 5 mg/10 day of medroxiprogesterone) or placebo. We measured plasma lipoperoxides, erythrocyte superoxide dismutase and glutathione peroxidase, total plasma antioxidant status and uric acid, as OS markers. Alternative cut-off values of each parameter were defined and a stress score (SS) ranging from 0 to 7 was used as total OS. MetS was defined according to National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATPIII) criteria. Participants were seen at baseline, 3 and 6 months. After 6 months, MetS decreased in MSW-HT (48%), their triglycerides and high-density lipoprotein cholesterol (HDL-c) improved; in the other groups no difference was found. SS in MSW-HT decreased (3.8 &plusmn; 0.3 to 1.7 &plusmn; 0.3, p &lt; 0.05) and OS was also reduced (44%), this effect was evident since 3 mo. HW-HT with high OS also decreased (40%). In placebo groups there was no change. Our findings suggest that HT improve lipids and OS associated to MetS in postmenopausal women.

No MeSH data available.


Related in: MedlinePlus